enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Canine leishmaniasis - Wikipedia

    en.wikipedia.org/wiki/Canine_leishmaniasis

    A dog displaying a typical clinical picture of visceral leishmaniasis. Canine leishmaniasis (LEESH-ma-NIGH-ah-sis) is a zoonotic disease (see human leishmaniasis) caused by Leishmania parasites transmitted by the bite of an infected phlebotomine sandfly.

  3. Favezelimab/pembrolizumab - Wikipedia

    en.wikipedia.org/wiki/Favezelimab/pembrolizumab

    Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more

  4. Pembrolizumab - Wikipedia

    en.wikipedia.org/wiki/Pembrolizumab

    Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...

  5. Sudden acquired retinal degeneration syndrome - Wikipedia

    en.wikipedia.org/wiki/Sudden_acquired_retinal...

    Despite similar symptoms and blood test results to Cushing's disease, evaluation of dogs with SARDS did not reveal any tumors in the pituitary or adrenal glands, [9] and recent work has indicated significant differences in the clinical and laboratory test parameters between the two diseases.

  6. Lenvatinib - Wikipedia

    en.wikipedia.org/wiki/Lenvatinib

    Lenvatinib is metabolized by the liver enzyme CYP3A4 to desmethyl-lenvatinib (M2). M2 and lenvatinib itself are oxidized by aldehyde oxidase (AO) to substances called M2' and M3', [10] the main metabolites in the feces. Another metabolite, also mediated by a CYP enzyme, is the N-oxide M3. Non-enzymatic metabolization also occurs, resulting in a ...

  7. PD-1 and PD-L1 inhibitors - Wikipedia

    en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

    Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma .

  8. Wikipedia:WikiProject Medicine/Lists of pages/Articles ...

    en.wikipedia.org/wiki/Wikipedia:WikiProject...

    Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file

  9. Renal cell carcinoma - Wikipedia

    en.wikipedia.org/wiki/Renal_cell_carcinoma

    For patients with metastatic cancer, sunitinib probably results in more progression of the cancer than pembrolizumab, axitinib and avelumab. [95] In comparison to pembrolizumab and axitinib, it probably results in more death, but it may slightly reduce serious unwanted effects. [ 95 ]